PYHIN1

Across TCGA pan-cancer cohorts, PYHIN1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PYHIN1 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher PYHIN1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PYHIN1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

PRAD, UCEC, and LIHC are the cancer types where PYHIN1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	OS	Median	All	0.125	0.883	<.001	12	view →
UCEC	DFS	Median	II,III,IV	0.873	0.434	.029	10	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →
SKCM	OS	Median	II,III,IV	0.956	0.832	.018	5	view →
LUAD	OS	Median	All	0.155	0.370	.019	3	view →
ESCA	DFS	Median	All	0.146	0.533	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PYHIN1–PRAD (OS)

Open the PRAD breakdown →